MCID: ALC006
MIFTS: 60

Alcoholic Hepatitis

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Alcoholic Hepatitis

MalaCards integrated aliases for Alcoholic Hepatitis:

Name: Alcoholic Hepatitis 12 75 15 33
Acute Alcoholic Liver Disease 12 72
Acute Alcoholic Hepatitis 12 55
Hepatitis, Alcoholic 17 72
Hepatitis Alcoholic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:12351
ICD9CM 35 571.1
NCIt 50 C34352
SNOMED-CT 68 9953008
ICD10 33 K70.1
UMLS 72 C0001306 C0019187

Summaries for Alcoholic Hepatitis

MalaCards based summary : Alcoholic Hepatitis, also known as acute alcoholic liver disease, is related to fatty liver disease and hepatic coma. An important gene associated with Alcoholic Hepatitis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Caspofungin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver, neutrophil and testes, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia : 75 Alcoholic hepatitis is hepatitis (inflammation of the liver) due to excessive intake of alcohol. It is... more...

Related Diseases for Alcoholic Hepatitis

Diseases related to Alcoholic Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 32.2 TNF SLC17A5 IL6 CYP2E1 CXCL8
2 hepatic coma 31.4 GPT F2 ALB
3 hepatitis 31.2 TNF SLC17A5 KRT18 GPT F2
4 fatty liver disease, nonalcoholic 1 31.0 SLC17A5 KRT18 GPT
5 portal hypertension 30.8 TNF GPT F2 ALB
6 antipyrine metabolism 30.5 F2 ALB
7 acute respiratory distress syndrome 30.5 TNF IL6 CXCL8
8 acute liver failure 30.4 SLC17A5 GPT F2 ALB
9 hepatitis a 30.4 TNF IL10 GPT F2 ALB
10 fournier gangrene 30.3 F2 ALB
11 hepatic encephalopathy 30.3 TNF SLC17A5 IL6 GPT F2 ALB
12 kwashiorkor 30.2 SLC17A5 GPT F2 ALB
13 eclampsia 30.1 TNF F2 ALB
14 bilirubin metabolic disorder 30.1 SLC17A5 GPT F2 ALB ADAMTS13
15 hepatitis e 30.0 TNF GPT F2 ALB
16 alcoholic liver cirrhosis 30.0 SLC17A5 F2 CYP2E1 CXCL8 ALB
17 acute pancreatitis 30.0 IL6 IL10 CXCL8
18 q fever 29.9 TNF IL6 IL10
19 purpura 29.9 TNF IL6 F2 ADAMTS13
20 hepatitis b 29.9 TNF SLC17A5 GPT F2 ALB
21 liver cirrhosis 29.9 SLC17A5 KRT18 GPT F2 CYP2E1 ALB
22 infantile liver failure syndrome 1 29.8 SLC17A5 GPT F2 ALB
23 cryptogenic cirrhosis 29.8 KRT18 F2
24 protein-energy malnutrition 29.7 TNF IL6 GPT ALB
25 viral hepatitis 29.7 TNF SLC17A5 KRT18 GPT F2 ALB
26 toxic shock syndrome 29.6 TNF IL6 IL10 CXCL8
27 cholangitis 29.6 TNF IL6 GPT F2 ALB
28 kaposi sarcoma 29.6 IL6 ICAM1 CXCL8
29 cholecystitis 29.4 KRT18 GPT F2 ALB
30 cytomegalovirus infection 29.4 TNF IL6 CXCL8 CCL2
31 acute cystitis 29.4 IL6 CXCL8 CCL2 ALB
32 liver disease 29.2 TNF SLC17A5 KRT18 IL6 GPT F2
33 vasculitis 29.2 TNF ICAM1 CCL2
34 glomerulonephritis 29.1 ICAM1 CCL2 ALB
35 pre-eclampsia 29.1 IL6 IL10 ICAM1 F2
36 pulmonary disease, chronic obstructive 29.1 TNF IL6 CXCL8 CCL2
37 atherosclerosis susceptibility 29.0 TNF IL6 ICAM1 CCL2
38 pneumonia 28.7 TNF IL6 IL10 CXCL8 CCL2
39 obstructive jaundice 28.7 TNF SLC17A5 IL6 GPT F2 CXCL8
40 bacterial infectious disease 28.4 TNF LBP IL6 IL10 CXCL8 CCL2
41 body mass index quantitative trait locus 11 28.3 TNF IL6 GPT CYP2E1 CCL2
42 endocarditis 28.0 TNF LBP IL6 IL10 F2 CXCL8
43 proteasome-associated autoinflammatory syndrome 1 27.8 TNF IL6 IL10 ICAM1 CXCL8 CCL2
44 peritonitis 27.0 TNF LBP IL6 IL10 ICAM1 F2
45 exudative glomerulonephritis 10.7 TNF CXCL8
46 scorpion envenomation 10.7 TNF IL6
47 non-a-e hepatitis 10.7 F2 ALB
48 marburg hemorrhagic fever 10.7 TNF F2
49 paraquat poisoning 10.7 SLC17A5 GPT
50 hepatoportal sclerosis 10.6 GPT F2

Comorbidity relations with Alcoholic Hepatitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcoholic Gastritis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Deficiency Anemia Fatty Liver Disease
Hepatic Encephalopathy Portal Hypertension
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Alcoholic Hepatitis:



Diseases related to Alcoholic Hepatitis

Symptoms & Phenotypes for Alcoholic Hepatitis

MGI Mouse Phenotypes related to Alcoholic Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.85 ADAMTS13 ALB CYP2E1 F2 ICAM1 IL10
2 liver/biliary system MP:0005370 9.5 ALB CYP2E1 IL10 IL6 KRT18 LBP
3 neoplasm MP:0002006 9.1 ALB CYP2E1 ICAM1 IL10 IL6 TNF

Drugs & Therapeutics for Alcoholic Hepatitis

Drugs for Alcoholic Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
5
Lenograstim Approved, Investigational Phase 4 135968-09-1
6
Metformin Approved Phase 4 657-24-9 4091 14219
7
Choline Approved, Nutraceutical Phase 4 62-49-7 305
8
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
9
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
12 Nootropic Agents Phase 4
13 Polyene phosphatidylcholine Phase 4
14 Lecithin Phase 4
15 Anti-Infective Agents, Local Phase 4
16 Central Nervous System Depressants Phase 4
17 Anti-Infective Agents Phase 4
18 Antifungal Agents Phase 4
19 Pharmaceutical Solutions Phase 4
20 Nutrients Phase 4
21 Micronutrients Phase 4
22 Trace Elements Phase 4
23 N-monoacetylcystine Phase 4
24 Antidotes Phase 4
25 Respiratory System Agents Phase 4
26 Expectorants Phase 4
27 cysteine Phase 4
28 Metadoxine Phase 4
29 Vitamins Phase 4
30 Folate Phase 4
31 Vitamin B 6 Phase 4
32 Vitamin B9 Phase 4
33 Vitamin B Complex Phase 4
34 Immunologic Factors Phase 4
35 Adjuvants, Immunologic Phase 4
36
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
37
Norfloxacin Approved Phase 3 70458-96-7 4539
38
Propranolol Approved, Investigational Phase 3 525-66-6 4946
39
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
40
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
41 Ethiodized oil Approved, Investigational Phase 3 8008-53-5
42
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
43
Rifaximin Approved, Investigational Phase 2, Phase 3 80621-81-4 46783403 6436173
44
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
45
Lactulose Approved Phase 2, Phase 3 4618-18-2 11333
46
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
47
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
48
Atorvastatin Approved Phase 3 134523-00-5 60823
49
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
50 Vasodilator Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
2 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
3 Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis Completed NCT02161653 Phase 4 Prednisone plus Metadoxine;Pentoxifylline plus Metadoxine
4 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
5 Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients Completed NCT01413360 Phase 4 High dose vitamin C
6 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
7 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Completed NCT01501162 Phase 4 hepatitis, alcohol, probiotics;alcohol, hepatitis, Placebo
8 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Recruiting NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
9 Granulocyte Colony Stimulating Factor in Alcoholic Hepatitis Recruiting NCT03703674 Phase 4 GCSF
10 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Recruiting NCT02051842 Phase 4 Metadoxine
11 Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis Unknown status NCT02485106 Phase 3 Rifaximin;Corticosteroid or pentoxifylline
12 Principal Investigator Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
13 COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST Unknown status NCT01134692 Phase 3 Propranolol, Norfloxacin, VSL#3
14 Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Completed NCT01809132 Phase 2, Phase 3 Anakinra;Pentoxifylline;Zinc Sulfate;Methylprednisolone
15 N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial Completed NCT00962442 Phase 3 N-Acetylcysteine;placebo
16 Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study. Completed NCT00863785 Phase 3 Corticoids plus N Acetyl Cysteine
17 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Completed NCT01471028 Phase 3
18 Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
19 Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects With Acute On Chronic Hepatitis (AOCH) Completed NCT00973817 Phase 2, Phase 3
20 A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
21 Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial) Completed NCT01143246 Phase 3 Terlipressin;Placebo
22 Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF) Completed NCT01383460 Phase 3 Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO);Placebo
23 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
24 The Mechanism of Action of N-acetylcysteine for Reducing the Risk of Infection in Alcoholic Hepatitis Recruiting NCT03069300 Phase 3 N-acetyl cysteine (NAC)
25 Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study Recruiting NCT02442180 Phase 3 G-CSF (Filgrastim injection);steroid;placebo
26 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Recruiting NCT02473341 Phase 3 Bovine Colostrum;Placebo
27 Granulocyte Colony Stimulating Factor Therapy In Decompensated Cirrhosis Of Liver: A Double Blinded Single Centre Randomised Controlled Trial Recruiting NCT03911037 Phase 2, Phase 3 G-CSF;Placebo
28 Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis Active, not recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
29 Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina Active, not recruiting NCT03696940 Phase 3 L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg;Atorvastatin 10mg
30 Therapeutic Plasma Exchange in Patients With Acute on Chronic Liver Failure: A Randomized Controlled Trial (PLEXAR) Not yet recruiting NCT04051437 Phase 3 Standard medical treatment
31 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
32 A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Terminated NCT02612428 Phase 3
33 Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817) Withdrawn NCT01452295 Phase 2, Phase 3 ELAD (Extracorporeal Liver Assist System)
34 Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
35 A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
36 A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Completed NCT02039219 Phase 2 Placebo;10 mg Obeticholic Acid (OCA)
37 An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis Completed NCT02655510 Phase 1, Phase 2 F-652
38 A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Completed NCT02019056 Phase 2 Placebo /bid P.O;MG-1;MG-2 : MG1000mg, Placebo /bid P.O;metadoxine
39 A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis Completed NCT01968382 Phase 2 IMM 124-E (Hyperimmune Bovine Colostrum);Placebo (High protein milk powder)
40 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis Completed NCT01903798 Phase 2 Mycophenolate mofetil;Prednisolone;Rilonacept
41 Efficacy of Combination Therapy of Glucocorticoids, and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis: A Pilot Study. Completed NCT02265328 Phase 2
42 Effect of Oral S-Adenosylmethionine Administration on Abnormalities of Hepatic Methionine Metabolism and Disease Progression in Alcoholic Liver Disease. A Randomized, Double Blind, Placebo-controlled Trial Completed NCT00851981 Phase 2
43 Long-Term Treatment of Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00062764 Phase 2 Actos (Pioglitazone)
44 Treatment of Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00013598 Phase 2 Pioglitazone
45 An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis Recruiting NCT03432260 Phase 2 DUR-928
46 Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Recruiting NCT03829683 Phase 2 Vitamin C;Dextrose 5% in water
47 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis Recruiting NCT02776059 Phase 2 Standard of care + pegfiltrastim;Standard of care
48 IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH) Recruiting NCT03775109 Phase 2 Canakinumab 150mg/ml solution for injection;Placebo
49 The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Active, not recruiting NCT03294941 Phase 2
50 A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis. Not yet recruiting NCT03452540 Phase 2 DS102

Search NIH Clinical Center for Alcoholic Hepatitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Pentoxifylline
Prednisolone
Propylthiouracil

Genetic Tests for Alcoholic Hepatitis

Anatomical Context for Alcoholic Hepatitis

MalaCards organs/tissues related to Alcoholic Hepatitis:

41
Liver, Neutrophil, Testes, Brain, T Cells, Monocytes, Kidney

Publications for Alcoholic Hepatitis

Articles related to Alcoholic Hepatitis:

(show top 50) (show all 2615)
# Title Authors PMID Year
1
Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia. 9 38
19094193 2010
2
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 9 38
19769633 2009
3
Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. 9 38
19834427 2009
4
[Hepato-biliary and pancreatic disease and osteodystrophy]. 9 38
19721198 2009
5
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 9 38
19663083 2009
6
Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. 9 38
18618253 2009
7
Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. 9 38
19175915 2009
8
Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. 9 38
19033535 2009
9
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. 9 38
18848937 2008
10
Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. 9 38
19038698 2008
11
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. 9 38
18687753 2008
12
Serum TNF-alpha levels in relation to alcohol consumption and common TNF gene polymorphisms. 9 38
18579335 2008
13
Potential role of ADAMTS13 in the progression of alcoholic hepatitis. 9 38
19630717 2008
14
The -308 TNFalpha gene polymorphism in severe acute alcoholic hepatitis: identification of a new susceptibility marker. 9 38
18336639 2008
15
High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. 9 38
17498256 2007
16
Serum concentrations of interleukin-8 in relation to different levels of alcohol consumption. 9 38
17576072 2007
17
Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. 9 38
17331172 2007
18
[Utility of analytical parameters in the diagnosis of liver disease]. 9 38
17373869 2007
19
Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. 9 38
17331163 2007
20
New treatments of hepatorenal syndrome. 9 38
16850375 2006
21
Combined polymorphisms of tumour necrosis factor alpha and interleukin-10 genes in patients with alcoholic hepatitis. 9 38
16702858 2006
22
Severe alcoholic hepatitis with extremely high neutrophil count successfully treated by granulocytapheresis. 9 38
16508230 2006
23
[Serum cytokine concentration as prognostic factor in patients with alcoholic liver disease]. 9 38
17036498 2006
24
Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. 9 38
16762691 2006
25
Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. 9 38
16385229 2005
26
[Genetic susceptibility to the development of acute alcoholic hepatitis: role of genetic mutations in dehydrogenase alcohol, aldehyde dehydrogenase and cytochrome P450 2E1]. 9 38
16324524 2005
27
Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. 9 38
16344606 2005
28
Apoptosis in liver diseases--detection and therapeutic applications. 9 38
16258409 2005
29
Modifications in P62 occur due to proteasome inhibition in alcoholic liver disease. 9 38
15964033 2005
30
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. 9 38
16009691 2005
31
Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. 9 38
15878216 2005
32
Expression of apolipoprotein AI mRNA in peripheral white blood cells of patients with alcoholic liver disease. 9 38
15949702 2005
33
Effects of acetaldehyde and TNF alpha on the inhibitory kappa B-alpha protein and nuclear factor kappa B activation in hepatic stellate cells. 9 38
15550448 2005
34
Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. 9 38
15864177 2005
35
Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. 9 38
15601573 2004
36
Relation of tumor necrosis factor (TNF) gene polymorphisms with serum concentrations and in vitro production of TNF-alpha and interleukin-8 in heavy drinkers. 9 38
15902922 2004
37
Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. 9 38
15331349 2004
38
Serum levels of tissue polypeptide specific antigen are correlated with hepatocyte cytokeratin expression in alcoholic liver disease. 9 38
15365314 2004
39
Diagnosis and therapy of alcoholic liver disease. 9 38
15349802 2004
40
Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. 9 38
15288471 2004
41
Effect of prostaglandin E receptor subtype EP4 selective agonist on the secretion of tumor necrosis factor-alpha by macrophages in acute ethanol-loaded rats. 9 38
15318098 2004
42
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. 9 38
15122768 2004
43
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. 9 38
15046213 2004
44
New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. 9 38
14720455 2004
45
The effect of alcohol consumption on endothelial adhesion molecule expression. 9 38
14690873 2003
46
Hepatorenal syndrome. 9 38
14654322 2003
47
Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. 9 38
12865279 2003
48
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. 9 38
12663232 2003
49
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? 9 38
12663246 2003
50
Tumor necrosis factor alpha (TNF-alpha)-induced RANTES chemokine expression via activation of NF-kappaB and p38 MAP kinase: roles of TNF-alpha in alcoholic liver diseases. 9 38
12663241 2003

Variations for Alcoholic Hepatitis

Expression for Alcoholic Hepatitis

LifeMap Discovery
Genes differentially expressed in tissues of Alcoholic Hepatitis patients vs. healthy controls: 35 (show top 50) (show all 111)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) Liver + 8.79 0.000
2 KRT23 keratin 23, type I Liver + 7.04 0.000
3 FOS FBJ murine osteosarcoma viral oncogene homolog Liver - 6.75 0.000
4 CCL20 chemokine (C-C motif) ligand 20 Liver + 6.56 0.000
5 KCNN2 potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2 Liver - 6.11 0.000
6 SPINK1 serine peptidase inhibitor, Kazal type 1 Liver + 6.07 0.000
7 SPP1 secreted phosphoprotein 1 Liver + 6.04 0.000
8 LCN2 lipocalin 2 Liver + 5.74 0.000
9 CXCL6 chemokine (C-X-C motif) ligand 6 Liver + 5.55 0.000
10 COL1A2 collagen, type I, alpha 2 Liver + 5.33 0.000
11 FOSB FBJ murine osteosarcoma viral oncogene homolog B Liver - 5.08 0.000
12 LOXL4 lysyl oxidase-like 4 Liver + 5.01 0.000
13 PDZK1IP1 PDZK1 interacting protein 1 Liver + 4.95 0.000
14 CYP1A2 cytochrome P450, family 1, subfamily A, polypeptide 2 Liver - 4.91 0.000
15 GOLM1 golgi membrane protein 1 Liver + 4.87 0.000
16 NR4A2 nuclear receptor subfamily 4, group A, member 2 Liver - 4.85 0.000
17 MMP7 matrix metallopeptidase 7 Liver + 4.73 0.000
18 EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 Liver + 4.63 0.000
19 CD24 CD24 molecule Liver + 4.57 0.000
20 GNMT glycine N-methyltransferase Liver - 4.50 0.000
21 PCOLCE2 procollagen C-endopeptidase enhancer 2 Liver - 4.48 0.000
22 CYP2C19 cytochrome P450, family 2, subfamily C, polypeptide 19 Liver - 4.45 0.000
23 TACSTD2 tumor-associated calcium signal transducer 2 Liver + 4.41 0.000
24 DCDC2 doublecortin domain containing 2 Liver + 4.28 0.000
25 EPCAM epithelial cell adhesion molecule Liver + 4.26 0.000
26 NQO1 NAD(P)H dehydrogenase, quinone 1 Liver + 4.10 0.000
27 MT1M metallothionein 1M Liver - 4.07 0.000
28 SOX9 SRY (sex determining region Y)-box 9 Liver + 3.99 0.000
29 THBS2 thrombospondin 2 Liver + 3.98 0.000
30 KRT7 keratin 7, type II Liver + 3.96 0.000
31 BICC1 BicC family RNA binding protein 1 Liver + 3.96 0.000
32 FABP4 fatty acid binding protein 4, adipocyte Liver + 3.94 0.000
33 IL32 interleukin 32 Liver + 3.94 0.000
34 PPP1R1A protein phosphatase 1, regulatory (inhibitor) subunit 1A Liver - 3.91 0.000
35 RRM2 ribonucleotide reductase M2 Liver + 3.90 0.000
36 CXCL8 chemokine (C-X-C motif) ligand 8 Liver + 3.90 0.000
37 VCAN versican Liver + 3.90 0.000
38 COL1A1 collagen, type I, alpha 1 Liver + 3.89 0.000
39 DUSP1 dual specificity phosphatase 1 Liver - 3.89 0.000
40 LGSN lengsin, lens protein with glutamine synthetase domain Liver - 3.78 0.000
41 COL5A1 collagen, type V, alpha 1 Liver + 3.77 0.000
42 SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 Liver - 3.77 0.000
43 RGS4 regulator of G-protein signaling 4 Liver + 3.76 0.000
44 STMN2 stathmin 2 Liver + 3.72 0.000
45 SOX4 SRY (sex determining region Y)-box 4 Liver + 3.71 0.000
46 CLEC4M C-type lectin domain family 4, member M Liver - 3.69 0.000
47 ANXA2 annexin A2 Liver + 3.67 0.000
48 ANXA2P2 annexin A2 pseudogene 2 Liver + 3.66 0.000
49 CNDP1 carnosine dipeptidase 1 (metallopeptidase M20 family) Liver - 3.65 0.000
50 GPR88 G protein-coupled receptor 88 Liver - 3.64 0.000
Search GEO for disease gene expression data for Alcoholic Hepatitis.

Pathways for Alcoholic Hepatitis

Pathways related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 TNF IL6 IL22 IL10 ICAM1 F2
2
Show member pathways
13.27 TNF LBP IL6 IL22 IL10 ICAM1
3
Show member pathways
13.24 TNF IL6 IL22 IL10 CXCL8 CCL2
4
Show member pathways
13.06 TNF LBP IL6 IL10 CXCL8 CCL2
5
Show member pathways
12.9 TNF IL6 ICAM1 CXCL8 CCL2
6
Show member pathways
12.84 TNF IL6 IL22 IL10 ICAM1 CXCL8
7
Show member pathways
12.57 TNF IL6 IL10 F2 CCL2
8
Show member pathways
12.54 TNF IL6 IL22 IL10
9
Show member pathways
12.31 TNF IL6 CXCL8 CCL2
10
Show member pathways
12.28 TNF LBP IL6 CXCL8
11 12.22 TNF LBP IL6 IL10
12
Show member pathways
12.21 TNF IL6 IL10 CXCL8
13
Show member pathways
12.18 TNF LBP IL6 CXCL8
14
Show member pathways
12.18 TNF IL6 ICAM1 F2 CCL2 ALB
15 12.17 TNF IL6 IL10 CXCL8
16
Show member pathways
12.04 TNF IL6 IL22 IL10
17
Show member pathways
11.98 TNF IL6 F2
18
Show member pathways
11.97 IL6 IL22 IL10 ICAM1 CXCL8 CCL2
19 11.96 TNF IL6 ICAM1 CCL2
20 11.94 TNF IL6 IL10
21 11.93 TNF IL6 ICAM1 CXCL8 CCL2
22 11.9 TNF IL6 IL10 CXCL8
23 11.89 TNF LBP ICAM1 CXCL8
24
Show member pathways
11.85 LBP IL6 ICAM1 CXCL8
25 11.8 TNF IL6 ICAM1 CXCL8 CCL2
26 11.78 LBP IL6 CXCL8
27 11.78 IL6 ICAM1 CXCL8
28 11.76 TNF IL22 IL10
29 11.72 TNF IL6 IL10
30 11.72 TNF IL6 IL10 CXCL8
31 11.69 TNF IL6 ICAM1 CXCL8 CCL2
32 11.68 TNF IL6 IL10 CCL2
33
Show member pathways
11.61 TNF IL6 ICAM1 CXCL8
34 11.6 TNF IL6 CXCL8
35 11.6 TNF IL6 CXCL8 CCL2
36 11.52 TNF IL6 ICAM1
37 11.37 TNF IL6 IL10
38 11.35 IL6 CXCL8 CCL2
39 11.32 TNF IL6 IL10 ICAM1 CXCL8 CCL2
40 11.31 TNF IL6 IL22
41 11.3 TNF IL6 IL10 ICAM1
42 11.26 TNF IL6 IL10
43 11.22 TNF LBP IL6 IL10 ICAM1 CXCL8
44 11.17 ICAM1 F2 CCL2
45 11.12 TNF IL6 IL10 ICAM1 CXCL8 CCL2
46 11.02 TNF IL6 CXCL8
47 10.99 TNF IL6 IL22 IL10 CXCL8 CCL2
48 10.96 TNF IL6 IL22 IL10 CXCL8 CCL2
49 10.93 TNF ICAM1 CCL2

GO Terms for Alcoholic Hepatitis

Cellular components related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF LBP IL6 IL22 IL10 F2
2 endoplasmic reticulum lumen GO:0005788 9.46 IL6 F2 ALB ADAMTS13
3 extracellular space GO:0005615 9.4 TNF LBP IL6 IL22 IL10 ICAM1

Biological processes related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.96 TNF IL6 IL10 CXCL8 CCL2
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.81 TNF IL6 IL10
3 response to bacterium GO:0009617 9.8 SLC17A5 CYP2E1 CCL2
4 platelet activation GO:0030168 9.79 IL6 F2 ADAMTS13
5 cellular response to interferon-gamma GO:0071346 9.79 ICAM1 CCL2 ADAMTS13
6 defense response to Gram-positive bacterium GO:0050830 9.78 TNF LBP IL6
7 cellular response to interleukin-1 GO:0071347 9.76 ICAM1 CXCL8 CCL2
8 cellular response to tumor necrosis factor GO:0071356 9.73 ICAM1 CXCL8 CCL2 ADAMTS13
9 inflammatory response GO:0006954 9.73 TNF IL6 IL22 IL10 CXCL8 CCL2
10 positive regulation of interleukin-6 production GO:0032755 9.69 TNF LBP IL6
11 humoral immune response GO:0006959 9.67 TNF IL6 CCL2
12 embryonic digestive tract development GO:0048566 9.65 TNF CXCL8
13 positive regulation of macrophage activation GO:0043032 9.64 LBP IL10
14 positive regulation of glial cell proliferation GO:0060252 9.64 TNF IL6
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL10
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.63 TNF LBP CCL2
17 response to glucocorticoid GO:0051384 9.62 TNF IL6 IL22 IL10
18 response to molecule of bacterial origin GO:0002237 9.6 IL10 CXCL8
19 PERK-mediated unfolded protein response GO:0036499 9.59 CXCL8 CCL2
20 negative regulation of lipid storage GO:0010888 9.58 TNF IL6
21 positive regulation of chemokine production GO:0032722 9.58 TNF LBP IL6
22 endothelial cell apoptotic process GO:0072577 9.57 TNF IL10
23 cytokine-mediated signaling pathway GO:0019221 9.56 TNF LBP IL6 IL22 IL10 ICAM1
24 positive regulation of neuroinflammatory response GO:0150078 9.55 TNF IL6
25 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.54 TNF ICAM1
26 negative regulation of growth of symbiont in host GO:0044130 9.54 TNF LBP IL10
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.52 TNF IL10
28 receptor biosynthetic process GO:0032800 9.48 TNF IL10
29 acute-phase response GO:0006953 9.46 LBP IL6 IL22 F2
30 cellular response to lipopolysaccharide GO:0071222 9.23 TNF LBP IL6 IL10 ICAM1 CXCL8

Molecular functions related to Alcoholic Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL6 IL22 IL10 CXCL8 CCL2

Sources for Alcoholic Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....